Retinopathy Of Prematurity – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Retinopathy Of Prematurity – Pipeline Review, H2 2019’, provides an overview of the Retinopathy Of Prematurity pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinopathy Of Prematurity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity

– The report reviews pipeline therapeutics for Retinopathy Of Prematurity by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Retinopathy Of Prematurity therapeutics and enlists all their major and minor projects

– The report assesses Retinopathy Of Prematurity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Retinopathy Of Prematurity”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Retinopathy Of Prematurity

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Retinopathy Of Prematurity pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Advanced Imaging Projects Inc

Anida Pharma Inc

D. Western Therapeutics Institute Inc

Everglades Biopharma LLC

F. Hoffmann-La Roche Ltd

Insmed Inc

Novelty Nobility Inc

Orphanix GmbH

Protheragen Inc

Recordati SpA

Regeneron Pharmaceuticals Inc

Signablok Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Retinopathy Of Prematurity Overview

Retinopathy Of Prematurity Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Retinopathy Of Prematurity Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinopathy Of Prematurity Companies Involved in Therapeutics Development

D. Western Therapeutics Institute Inc

F. Hoffmann-La Roche Ltd

Insmed Inc

Protheragen Inc

Recordati SpA

Retinopathy Of Prematurity Drug Profiles

Drug for Retinopathy of Prematurity Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mecasermin rinfabate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit SCG3 for Diabetic Retinopathy and Retinopathy of Prematurity Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit SCG3 for Metabolic Disorders, Oncology and Ophthalmology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neuroprotectin D1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propranolol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Retinopathy of Prematurity Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis, Retinopathy Of Prematurity and Hemorrhagic Shock Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Retinopathy Of Prematurity Dormant Projects

Retinopathy Of Prematurity Product Development Milestones

Featured News & Press Releases

Jun 30, 2016: Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants

Jan 21, 2009: Insmed And Premacure Announce European Orphan Designation For IPLEX In Retinopathy Of Prematurity In Infants

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development for Retinopathy Of Prematurity, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Retinopathy Of Prematurity – Pipeline by Advanced Imaging Projects Inc, H2 2019

Retinopathy Of Prematurity – Pipeline by Anida Pharma Inc, H2 2019

Retinopathy Of Prematurity – Pipeline by D. Western Therapeutics Institute Inc, H2 2019

Retinopathy Of Prematurity – Pipeline by Everglades Biopharma LLC, H2 2019

Retinopathy Of Prematurity – Pipeline by F. Hoffmann-La Roche Ltd, H2 2019

Retinopathy Of Prematurity – Pipeline by Insmed Inc, H2 2019

Retinopathy Of Prematurity – Pipeline by Novelty Nobility Inc, H2 2019

Retinopathy Of Prematurity – Pipeline by Orphanix GmbH, H2 2019

Retinopathy Of Prematurity – Pipeline by Protheragen Inc, H2 2019

Retinopathy Of Prematurity – Pipeline by Recordati SpA, H2 2019

Retinopathy Of Prematurity – Pipeline by Regeneron Pharmaceuticals Inc, H2 2019

Retinopathy Of Prematurity – Pipeline by Signablok Inc, H2 2019

Retinopathy Of Prematurity – Dormant Projects, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Retinopathy Of Prematurity, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports